WHAT IS PROSTATE CANCER?
This year in the United States, almost 180,000 men will be told that they have prostate cancer. After a diagnosis of prostate cancer, a man and his family face several choices regarding treatment. Decisions involve many factors, personal as well as medical. Before making these decisions, it is very important to learn about all the options available. With this knowledge, a newly diagnosed prostate cancer patient can participate more confidently with his doctor in planning his individual treatment.
By age 50, about one-third of American men have microscopic signs of prostate cancer. By age 75, half to three-quarters of men will have some cancerous changes in their prostate glands. Most of these cancers remain latent, producing no signs of symptoms, or are so indolent, or slow-growing, that they never become a serious threat to health.
A much smaller number of men will actually be treated for prostate cancer. About 16 percent of American men will be diagnosed with prostate cancer during their lives; 8 percent will develop significant symptoms; and 3 percent will die of the disease.
UroLift® System for BPH
The UroLift® System treatment is a revolutionary, minimally invasive approach to treating an enlarged prostate, or BPH, that lifts or holds the enlarged prostate tissue out of the way so it no longer blocks the urethra. There is no cutting, heating or removal of prostate tissue.
Clinical data has shown that the UroLift System treatment is safe and effective in relieving lower urinary tract symptoms due to BPH without compromising sexual function. The goal of the UroLift System treatment is to relieve symptoms so you can get back to your life and resume your daily activities.
Most common side effects are light blood in the urine, some pain or discomfort when urinating, some increased urge to go and discomfort in the pelvis that typically resolve within two to four weeks after the procedure.